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Abstract 
Background 
Schizophrenia is a neurodevelopmental disorder with a variable course, often resulting in a severe 
functional impairment. The data indicate that more than 50% of patients do not receive timely and 
adequate treatment. The European Brain Council (EBC) project “The Value of Treatment” (VoT) 
aimed to provide evidence-based and cost-effective policy recommendations for a patient-centered 
and sustainable coordinated care model for brain disorders. The objective of the first part of 
schizophrenia study was to examine the needs and gaps in the patients' care pathway and to identify 
opportunities for improvements.  
Methods 
Working group of mental health experts, patient and pharmaceutical industry representatives 
analyzed cases studies illustrating the model of the patient journey. Descriptive analysis was based 
on an original inventory of needs and treatment opportunities, using focus group sessions, expert 
interviews, users’ input, and literature review. We focused on three highly relevant patient 
pathways: indicated prevention, reducing the duration of untreated psychosis, and relapse 
prevention.  
Results 
The reviewed data suggested a significant overlap between the patient/family and professional 
perspectives. The analysis identified several critical barriers to optimal treatment that need to be 
improved. Available health care services often miss or delay detection of symptoms and/or diagnosis 
in at-risk individuals. There is a lack of illness awareness among patients, families, and the public; 
scarcity of information, training and education among primary care providers; stigmatizing beliefs 
towards schizophrenia patients. Early symptom recognition and timely intervention (reduction of 
duration of untreated psychosis) result in better overall outcome and prognosis. Effective 
pharmacological and non-pharmacological management, including rehabilitation services and 
psychosocial interventions, can lead to a functional recovery. The current model of care does not 
provide optimal management of schizophrenia. There is insufficient cooperation between health care 
and social care providers, patients and their families, inadequate utilization of pharmacological and 
psychosocial interventions, lacking patient monitoring, and low implementation of integrated 
community care. The results of our analysis have significant policy implications that we summed up 
into general recommendations.  
Conclusions 
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Early detection and early intervention programs, timely intervention, and relapse prevention are 
essential for effective management of the illness. Moreover, optimal management requires a 
paradigm shift from symptom control, achieving and maintaining remission, to the emphasis on 
recovery. Since the current health and social services are not able to accomplish this goal, effective 
mental health policies that can change the systems of care, are needed.  
Key words 
Schizophrenia, patient journey, prevention, treatment, recovery, mental health 
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1. Introduction 
Schizophrenia is frequently a chronic and progressively disabling illness with negative impact 
on all aspect of a person’s life [[1]]. It is a neurodevelopmental, highly heritable disorder with still 
poorly understood etiopathogenesis. The lifetime prevalence of schizophrenia is 0.8-1.5% of the 
population over 18 years; approximately 7-8 individuals out of 1,000 will be diagnosed with 
schizophrenia in their lifetime.  
The illness has a considerable negative impact not only on patients' health and well-being, 
but also on their immediate environment, posing a substantial burden for primary caregivers and 
families. The costs of the illness management are high both for individuals and society [[1]]. Mortality 
rates are approximately two to three times higher than those of the general population, due to both 
natural (attributable to a variety of somatic conditions) and unnatural causes (accidents, suicides), 
resulting in reduced life expectancy of 15 to 20 years [[3]]. Comorbid medical conditions, including 
consequences of life-style factors (e.g., smoking) and sub-optimal treatment of physical disorders, 
contribute to about 60% of the excess mortality; the lifetime rate of suicide risk in schizophrenia is 
approximately 5% [[4],[5]].  
Schizophrenia is a clinically heterogeneous illness, already described as 'a group of 
schizophrenias' by E. Bleuler (1911) [[6]]. It is characterized by several symptom domains: positive 
symptoms (hallucinations, delusions), disorganized thoughts and speech, behavioral disturbances 
and psychomotor symptoms (agitation, catatonia), negative symptoms (social withdrawal, 
anhedonia, avolition, diminished speech, blunted affect), affective symptoms (depression, anxiety, 
manic symptoms), and cognitive symptoms (memory impairment, impaired concentration, 
difficulties with planning of daily tasks) [[4]].  
Symptoms follow a typical path of development from a premorbid phase with detectable 
cognitive, motor or social deficits, through a prodromal phase characterized by brief, attenuated 
positive symptoms, and/or functional decline [[4]]. Alternatively, sudden onset of psychosis is also 
possible. Fully developed illness manifests itself as an acute psychotic phase with positive symptoms, 
resulting in a post-acute and subsequently a stable phase with negative and cognitive symptoms, 
subthreshold or residual positive symptoms, social and functional impairment [[4]].   
The course of illness is highly variable, typically episodic, with exacerbations and remissions. 
Frequent relapses contribute to neurobiological impairment, further functional and social decline, 
and poor treatment response [[7], [8]]. Relapse can be defined as a return of illness or symptoms 
after partial recovery; recurrence is a reappearance of illness after full remission or recovery. 
Exacerbation of illness might be triggered by drug withdrawal, non-specific psychosocial stressful 
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situations (e.g., stress in professional environment, academic, personal life [relational distress]), or 
substance misuse. Schizophrenia outcome is a multidimensional concept that includes domains of 
psychopathology, social functioning, life-span and various aspects of quality of life, and societal 
impact [[4]]. Commonly cited predictors of more favorable outcome are acute onset of illness, good 
premorbid functioning, better cognitive function, absence of substance abuse, female gender, and a 
later age of onset.   
More than 50% of schizophrenia patients suffer from intermittent but long-term psychiatric 
problems and approximately the same number of them has unfavorable outcome with chronic 
symptoms and disability, varying across countries [[9],[10],[11]]. It has been shown that even chronic 
illness can be effectively managed. Recovery and social reintegration through adequate treatment 
and care is possible in many cases, up to 20% of patients meet defined criteria of recovery [[12]]. 
However, data indicate that more than 50% of people with schizophrenia do not receive appropriate, 
timely, and adequate treatment. According to the World Health Organization, the median treatment 
gap for schizophrenia is 69%, in low-income countries even as high as 89% [[13]].  
2. Study objectives  
 More than a decade ago, the European Brain Council (EBC) published a report “The Economic 
Cost of Brain Disorders in Europe” [[14]]. An updated report from 2010 estimated the total cost 
(direct healthcare and non-medical plus indirect) of psychotic disorders (including schizophrenia) in 
Europe at 93.9 billion Euros, 18,796 EUR per patient [[15]]. As expected, the majority of costs, 69%, is 
attributed to the indirect, non-medical costs that do not cover direct medical and non-medical 
treatment expenses.     
 In 2016, EBC launched a new project, “The Value of Treatment” (VoT) that aimed to address 
equality gaps across the EU in early detection and intervention, diagnostics and treatments for brain 
(including mental) disorders. The ultimate goal was to provide evidence-based and cost-effective 
policy recommendations for the adoption and implementation of a more patient-centered and 
sustainable coordinated care model for brain disorders [0]. 
 The VoT project focused on a number of neurological conditions and, as a single psychiatric 
disorder, schizophrenia. Working groups, composed by experts of the EBC member organizations, 
representatives of patient and family organizations, health policy and economic experts, and drug 
companies developed case studies for each disorder. The aim was to analyze the socioeconomic 
impact and health gains of selected evidence-based healthcare interventions in comparison with the 
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cost of current care/non-treatment by carrying out combined cost-effectiveness evaluation of 
selected care pathway services and patients' journey and care modeling.  
In this paper, we present the findings from the patients' care pathway analysis in 
schizophrenia. The objective was to examine the needs and identify gaps and opportunities for 
improvements in the current care pathway. The results of the second part, economic modeling 
assessing socioeconomic impact of specific clinical interventions targeted to close some of the gaps 
identified in the patient journey analysis, are presented in a separate paper [[17]]. 
The patient journey is a description of how patients experience a disease or condition from 
their first awareness of symptoms through all stages of the illness. The patient journey can represent 
an alternative view on mental illness, based on person’s individual experience. It highlights the fact 
that the daily life experience of patients is diverse. Documenting the patient journey aims to identify 
key issues in the care for schizophrenia patients that need to be improved.  
3. Methods  
The schizophrenia working group, led by WG, consisted of the members of the Board of the 
European Psychiatric Association (EPA), representatives of the Global Alliance of Mental Illness 
Advocacy Networks-Europe (GAMIAN-Europe), the European Federation of Associations of Families 
of People with Mental Illness (EUFAMI), economic and mental health policy experts of London School 
of Economics (LSE), Erasmus School of Health Policy & Management, Erasmus University Rotterdam,  
the Czech National Institute of Mental Health (NIMH), and the representatives of pharmaceutical 
industry. The study was sponsored by the EBC.  
The care pathway of schizophrenia patients was analyzed in order to identify major barriers 
preventing patients from receiving timely and adequate treatment and care. The analysis served as 
the basis to develop consented recommendations on how to overcome them. The journey was based 
on an original inventory of needs and treatment opportunities, using focus group sessions, expert 
interviews, users’ input, and literature review. Due to the heterogeneous course of illness with highly 
diverse individual trajectories, we focused on three highly relevant patient pathways (Fig. 1):  
(1) Indicated prevention in individuals at risk of developing schizophrenia; 
(2) Reducing the duration of untreated psychosis by timely intervention in patients with manifest, 
but not yet diagnosed schizophrenia;  
(3) Relapse prevention in patients after a first episode of schizophrenia, and patients with episodic 
course of the illness.  
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---Fig. 1 about here---  
 
4. Results  
Patient and family members’ needs and their perspectives along the journey were collected 
through discussions with patient and family organizations and retrieved from published literature. 
The paramount points concerning crucial illness stages, from at risk states through recovery, are 
listed in the Table 1.  
---Table 1 about here--- 
a. Indicated prevention: needs and treatment gaps 
From a biomedical perspective, selective schizophrenia prevention is not possible yet, since 
there are no reliable biomarkers or other measures for valid prediction of illness onset [[24]]. 
Identifying individuals at risk of illness could improve early diagnosis, initiate timely treatment, and 
ultimately contribute to the prevention of psychotic disorders [[25]]. So far, population at-risk states 
can be detected only insufficiently clinically and genetically (e.g., based on family history) [[26]]. 
Additional nonspecific environmental risk factors include prenatal infection or malnutrition, perinatal 
complications, season of birth, urbanicity, cannabis use, history of migration, etc [[27]].   
More accessible preventive measures can be implemented in the population with manifest 
behavioral changes and nonspecific symptoms, such as odd thinking, social withdrawal, bizarre 
behavior, aggressiveness (i.e., indicated prevention). Effective prevention includes both early 
detection (identification of at-risk individuals, recognition of premorbid and prodromal changes) and 
early intervention (elimination of risk factors, preventive programs). The most typical periods for the 
onset of schizophrenia are late adolescence and early adulthood. Otherwise common displays of 
teens during puberty, adolescents, such as change of friends, giving up hobbies, worsening of school 
or academic performance, sleep problems, mood swings, irritability, can also be first signs of 
imminent psychosis, and can therefore make diagnosis difficult. Indicated prevention has a potential 
to prevent a transition to psychotic disorder.  
 Early detection   
First premorbid signs of psychosis include mild cognitive impairments, social deficits; 
prodromes manifest themselves as ‘attenuated psychotic symptoms’, or ‘brief limited 
intermittent psychotic symptoms’ [[28],[29]]. Early detection and intervention may reduce the risk of 
conversion into fully blown illness [[30]].  Diagnosis of psychosis is based on observed behavior, 
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subjective experiences, and reports from others who are familiar with the person [[31]]. Prodromal 
psychotic syndrome can be assessed using various measures (e.g., Structured interview for 
Prodromal syndromes, SIPS; Scale of Prodromal Symptoms, SOPS; At Risk Mental State, ARMS; Brief 
Limited Intermittent Psychotic Symptoms, BLIPS; Comprehensive Assessment of At-Risk Mental 
States; CAARMS) [[32],[33],[34]]. A combination of factors can predict schizophrenia in up to 80% of 
young teenagers who are at high risk of developing the illness. 
The first recognition of psychosis is frequently not made by healthcare professionals, but by 
family and teachers, in medical emergency services or police / criminal justice system. Thus, 
awareness campaigns need to train teachers, sport coaches, etc. how to identify young people at 
risk. High-risk adolescents might be screened for example on the presence of prodromal symptoms 
or the history of schizophrenia in first-degree relatives. If necessary, an intervention program that 
aims to improve stress resilience, suboptimal maturation of neuronal pathways, prevent or alleviate 
adverse environmental circumstances and insults, can be implemented [[19]].  
The setting for prevention would be schools, universities, workplaces, primary care (GP 
offices), or local public health authorities. A campaign underscoring the importance of an early 
diagnosis and intervention should also target first-line health care professionals, nurses, GP's, so they 
can refer patients to psychiatrists. It should be noted, that while prevention is usually funded from a 
budget of a single sector, prevention-related cost savings are beneficial across sectors. This makes it 
more difficult to persuade a single stakeholder to invest into the prevention. Convincing more 
stakeholders to take a joint action and invest into prevention together is a lengthy process, which 
requires highly developed diplomatic and negotiating skills. 
Studies showed that more than 20% of schizophrenia patients who experienced barriers to 
contact a doctor to treat their physical problems reported stigma and fear of disclosing their mental 
health problem to a GP [[35]]. Reduction of stigma associated with mental illness over time is 
feasible and may contribute to effective prevention [[36]]. Mental health awareness campaigns 
should use evidence-based strategies to eliminate or reduce stigma, this may subsequently also 
improve the early detection. [[37]] 
Media play an important role; thus, all campaigns should specifically address the negative 
image of mental illness and patients among general public. The term of ‘schizophrenia’ itself can be 
perceived negatively even by health professionals, other diagnoses are often given instead. 
Interestingly, some Asian countries (Japan, Korea) recently changed the term ‘schizophrenia’ into 
‘integration disorder’ or 'attunement disorder', respectively, which subsequently reduced 
stigmatization and fostered acceptance of diagnosis [[38]].  
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Early intervention  
Many of the affected individuals suffer considerably at early stage. Symptomatic treatment 
(psychosocial and/or pharmacological) is indicated at this stage, especially for those with a 
considerable degree of distress. Cognitive behavioral therapy (CBT) can reduce the risk of developing 
psychosis in those at high risk after a year and is recommended by the National Institute for Health 
and Care Excellence (NICE) [[39],Error! Reference source not found.]. Another preventive measure is 
to avoid psychoactive substances that have been associated with development of the disorder [[41]]. 
A number of interventions that have demonstrated efficacy in other conditions are beneficial in 
schizophrenia, as well (e.g., physical exercise) [[42]]. Preventive psychosocial interventions aim at 
stress reduction, educational campaigns inform about risks related to substance misuse, accessible 
and low-threshold services provide counseling, support, and safe social environment to interact with 
peers.  
Early intervention programs are already available in numerous countries. There are positive 
long-term experience from Australia (Personal Assessment and Crisis Evaluation Clinic, PACE), United 
Kingdom (Outreach and Support in South London, OASIS), Denmark (OPUS Study) and others 
[[43],[44],[45]]. The UK has implemented clinical guidelines and quality guidelines for such services, 
and the baseline auditing report has been published [[46]]. It reveals a large disparity in the services 
available across the UK, with some NHS Trusts offering the entire spectrum appropriately and others 
very little.  The same observation applies for a view across various countries. There are data 
supporting the effectiveness of early intervention programs aiming to prevent schizophrenia [[47]]. A 
meta-analysis of published studies suggested that it might be possible to delay or prevent transition 
to psychosis in individuals at high risk, using various (psychological, pharmacological, or nutritional) 
interventions, with the best evidence for CBT [[39]].  
b. Timely intervention for manifested psychosis: needs and treatment gaps  
Although the population screening process can be costly, early intervention services have 
been shown to yield significant savings in societal (health- and social-care, and productivity) costs 
through preventing hospitalizations, increasing employment rates and decreasing involvement with 
the criminal justice system [[48],[49]].  
For patients and their families, the acute psychotic outbreak is a moment of crisis. 
Emergency medical assistance is needed, often followed by hospital admission. Inpatient treatment 
is not necessary if well-organized outpatient services, mobile outreach teams, or low-threshold units 
(e.g., 24/7 crisis centers) are available. The first encounter and experience with psychiatric services 
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and treatment may determine not only patient’s attitude towards therapy, but also the future course 
and outcome of illness. Therefore, access to a psychiatric expert or unit should be improved. GP’s 
should refer the individual earlier to a specialized team; if they believe that the patient manifests 
with psychotic symptoms, they should refer him/her to a psychiatrist. Touchpoints for early diagnosis 
would be family and teachers who can reach out to psychology/counseling services. 
The period between the onset of psychosis and treatment initiation is critical. Duration of 
untreated psychosis (DUP) is defined as the time from the first manifestation of the first psychotic 
symptom emergence to initiation of adequate drug treatment [[50]]. DUP encompasses both 
extrinsic factors, such as the local legal provisions (i.e. requirement of dangerousness for involuntary 
treatment), accessibility to mental health services, and intrinsic, illness-related factors. Mean values 
of DUP range from 8 to 48 weeks, it is important to keep in mind that potential deterioration in 
schizophrenia occurs most aggressively in the first 2-3 years.   
The duration of untreated psychosis can serve as an indirect measure of the effectiveness of 
early detection strategies and also as a predictor of treatment outcome [[51],[52],[53]]. Length 
of DUP has been related to a poor treatment response, insufficient symptom control, prominent 
negative symptoms, and poor overall functional outcome (failure to achieve remission, decreased 
social functioning, lower quality of life) [[50]]. On the other hand, evidence of the impact of DUP on 
the brain structural abnormalities is not fully conclusive, mainly due to the methodological 
inconsistencies (e.g., small sample sizes), similarly as the equivocal effect on cognitive impairment.   
Early recognition and diagnosis, plus early intervention, can thus reduce the burden of 
schizophrenia; minimizing of DUP improves overall outcome and prognosis.  Timely treatment reduce 
the number and duration of hospitalizations over 1–2 years after a first episode of psychosis 
[[54],[55]], although the impact is less clear over the longer course of illness [[56],[57]]. 
c. Long-term management and relapse prevention: needs and treatment gaps 
One of the principal goals in the long-term management is to prevent relapses, maintain 
remission, and achieve functional recovery. Optimal illness management can positively influence the 
whole patient journey, as the vicious circle (psychotic episode, social withdrawal, quitting job/school, 
functional impairment, suicidal ideations, etc.) can be broken. Ideal treatment is characterized by 
adequate utilization of both the pharmacological and psychosocial interventions. Patients should 
consult on a regular basis a specialized team, to discuss their needs, short-term and long-term goals, 
treatment plans.  The role of a psychiatrist is to manage the treatment pathway of the patient. There 
is an important role of therapeutic guidelines, available evidence suggests that adherence to 
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guidelines improves patient outcomes, in contrast to treatment as usual, driven by clinical judgment 
only [[58],[59]] 
Schizophrenia is typically a multi-episodic disorder. Each relapse can worsen the course and 
outcome of the illness, reduce treatment response, have a severe negative impact on patients, their 
carers, and the whole health and social system [[8]]. Therefore, relapse prevention is essential for the 
management of schizophrenia. Among the factors that contribute to relapse/recurrence of illness, 
drug discontinuation plays a prominent role. Not only complete withdrawal of medication is 
hazardous, but also intermittent treatment jeopardizes patient’s well-being [[21]]. Continuous 
treatment has been shown to be paramount in the reduction of relapse risk; patients are able to stay 
relapse-free for a significantly longer period of time.   
Various sources report the rate of 40-50% schizophrenia patients who are non-adherent; 50-
55% of all hospitalizations can be attributed to non-adherence [[60]]. Adherence to antipsychotic 
medication can be improved by using long-acting injectable antipsychotics (LAI), also called “depot” 
[[61]].  The advantage of LAI in comparison with oral formulations was not apparent in randomized 
controlled trials, since these tend to exclude non-adherent patients, and also generally increase 
adherence [[62],[63]]. True benefit of LAI has been shown in pragmatic naturalistic studies that enroll 
all ‘real-life’ patients, including those who are non-adherent, relapsing, non-cooperative, with 
comorbid physical conditions, with aggressive behavior [[64],[65]].   
Non-pharmacological interventions include psychoeducation, problem-oriented therapy, 
management of symptoms with cognitive-behavioral therapy (CBT), social skills training, cognitive 
remediation, etc. Involvement of the caregivers is very important: they need to be provided with 
information about the illness, psychoeducation on the importance of treatment continuity, how to 
recognize early symptoms of a new episode. Electronic systems monitoring early warning signs of 
imminent relapse (using text messages, apps, actigraphs) can be also employed. Telemetric warning 
signs monitoring (e.g., ITAREPS program) may significantly reduce the risk of relapse and help in 
timely intervention [[23],[66]]. Moreover, technology could be used to monitor stable patients. The 
follow-up of patients on regular basis (monthly, bi-monthly, or three-monthly) could be automatic: 
i.e. electronic reminders sent to the patient and caregivers with a text indicating that the patient has 
an appointment. If the patient does not show up, a member of the assertive outreach mobile team 
or the informal carer can visit the patient at home [[67]].  
Although insight (self-awareness of illness) is a prerequisite for therapy adherence and self-
management, it might not be easily achieved [[68]]. Self-awareness of illness is a concept used to 
describe patient's acknowledgement of his/her strengths and limitations, in particular the ability to 
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understand the nature of impairment and recognize its implications. Patients may not believe they 
are ill and may deny the need for therapy or they may have such disorganized thinking that they 
cannot remember to take their daily doses. There is a range of interventions that facilitate the 
development or improvement of self-awareness. Generally, it is believed that an individualized 
approach to address impairments of self-awareness is necessary: it takes into account whether the 
impairment of self-awareness is neurological, psychological or environmental in origin [[69]]. 
People with schizophrenia can take an active role in managing their own condition. Once 
they learn basic facts about the illness and its treatment, they can make informed decisions about 
their care, including pharmacotherapy, actively participate in shared decision on treatment and drug 
choice [[70]]. If patients know how to watch for the early warning signs of relapse and how to make a 
plan to respond, they can learn how to prevent relapses. Patients can also develop and use coping 
skills to deal with persistent symptoms. 
5. Discussion  
The value of treatment in psychiatry cannot be reduced to economic and financial aspects 
only. It is an asset for society, which can be measured as a value that an intervention provides to the 
patient and a “value for money” that the intervention provides to the payer. Thus, value comprises a 
combination of symptom reduction, improving quality of life, better social functioning, subjective 
well-being, physical health, guaranteed safety (e.g., suicide prevention programmes), and achieved 
cost-effectiveness. Long-term psychiatric treatment includes not only health care, but also requires 
resources and involvement of the social system. Comprehensive care should be provided and 
organised according to the patient’s needs (person-oriented care). This means an easily accessible 
and a seamlessly integrated care network which is aimed at improving quality of life, while respecting 
patients’ rights. Inevitable provisions of involuntary treatment or commitment in warranted cases 
must be regulated by the law, maintaining basic human rights. The network of care, where the 
patient is a partner, should consist of in- and out-patient services, community care centres, self-help 
groups, family organizations, psychiatrists, psychologists, nurses, social workers, case managers, and 
GP’s. Factors affecting patients' journey along the schizophrenia illness trajectory found in our care 
path analysis are summarized in the Table 2.  
---Table 2 about here--- 
The assessment of three pre-defined patient pathways (indicated prevention, reduction of 
untreated psychosis, relapse prevention) identified several critical barriers to optimal treatment.  
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Conspicuously, available health care services regularly miss or delay detection of symptoms 
and/or diagnosis. Current systems do not provide appropriate prevention for patients at risk and 
early detection services. Other contributing factors include lack of illness awareness among patients, 
families, and the public; lack of information, training and education among primary care providers; 
stigmatizing beliefs, prejudices and discriminating attitudes and actions towards schizophrenia 
patients. 
The typical experience of family members of schizophrenia patients with the first service 
contact is not through prevention/screening/early interventions; in almost all cases their journey 
started with a crisis. Therefore, there is a pressing need to move away from the classical model 
where doctors assume a passive role, sitting within the service facility, waiting for patients to "find" 
them. There is a strong consensus that broad availability of affordable, mobile services could prevent 
many crises, involuntary treatments, it could reduce harm.  
The prognosis of social and professional reintegration is negatively correlated with the 
number of episodes of illness. Longer duration of untreated psychosis, higher number of relapses 
make it more difficult to fully recover and recovery will take more time. Moreover, untreated illness 
is associated with substance abuse and increased risk of violent behavior. A major factor causing 
non-adherence to drug treatment, in addition to illness-related factors (lack of insight), is that 
patients are often not well informed on the medication side effects and/or how to manage them.  
Symptoms and cognitive impairment disrupt the psychosocial functioning of schizophrenia 
patients and often result in social problems, e.g., difficulties in relationships, giving up hobbies, 
decline in academic and/or work performance with subsequent economic and social decline [[71]]. 
The onset of illness during adolescence or young adulthood prevents patients from completing their 
academic or vocational training, establishing age-appropriate social relationships, initiating family 
life. Throughout the course of illness, impairments in adaptive life skills are a major source of 
disability. Many patients have difficulty keeping a job or taking care of themselves; thus, they have to 
rely on others to assist them. Stigmatizing attitudes and beliefs about schizophrenia are widespread 
and may interfere with patients’ willingness to discuss their problems and seek treatment. High 
unemployment rate, lower educational level and socioeconomic status compared to unaffected 
peers, with subsequent dependence on social welfare may also have a negative impact on real-life 
functioning. Moreover, schizophrenia is associated with poor physical health, premature death and 
suicide, prejudice (stigma) and discrimination in many facets of life [[72],[73]].  
On the other hand, if properly treated via integrated biopsychosocial approach (including 
optimal antipsychotic treatment combined with psychosocial interventions), people with 
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schizophrenia can live a fulfilling life. Effective, low-dose, safe and continuous antipsychotic 
treatment might lead to a functional recovery [[21]]. In the long-term management, the availability 
of rehabilitation programs is limited.  
Rehabilitation emphasizes social and vocational training to assist people with schizophrenia 
participate fully in their communities. Since the patients’ professional and social life trajectories are 
compromised, they need to develop new skills to reintegrate. Rehabilitation programs include 
employment services, money management counseling, cognitive remediation, and social skills 
training. These non-pharmacological interventions play an important role in the long-term 
schizophrenia management, improving overall functioning. Work reintegration is a frequently 
expressed goal for patients. While some patients cannot pursue their professional activity, many 
continue to work or wish to do so. The ability to keep a job with adequate support often results in 
improved quality of life and minimizes the negative financial impact and the risk of social exclusion.  
We can witness a shift from emphasis on symptom control, achieving and maintaining 
remission, to the functional recovery. This approach is supported by growing clinical evidence 
indicating that a certain degree of recovery is possible, despite the presence of residual symptoms, 
and that some people with schizophrenia actually may achieve full recovery [[74]].  
There are different definitions of recovery, clinical and patient-based [[75]]. The clinical 
recovery accentuates remission and functional improvement. Remission is defined as a 
reduction/absence of symptoms to the point that they do not interfere significantly with behavior, 
using clinical rating scales [[76],[77]]. Functional improvement implies the ability to function in the 
community, socially and vocationally living independently, having friends, etc. The patient-based 
definition of recovery has been developed based on personal experiences of people with mental 
illness [[75]]. The most frequently used definition is: “the development of new meaning and purpose 
in one’s life, as one grows beyond the catastrophic effects of mental illness.” [[78]] Recovery from 
schizophrenia is a highly individual process. The four key processes of personal recovery are finding 
hope, re-establishment of identity, finding meaning in life, and taking responsibility for recovery. In 
other words: connectedness, hope, identity, meaning, and empowerment (the acronym “CHIME”) 
[[79],[80]].  
Recovery is not mere absence of symptoms, but a journey through which the person may 
achieve a meaningful life. Attaining an improved quality of life, physical health, social integration, 
instrumental competence and self-agency, independent living, and competitive employment can be 
seen as elements of a meaningful life, and therefore pursued to a variable degree, depending on the 
person and the context. 
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Our analysis of the patient journey showed that the current model of care does not provide 
optimal management of schizophrenia due to the poor collaboration among health and social care 
professionals and lack of continuity of the antipsychotic treatment. Furthermore, there is insufficient 
cooperation between care providers and patients and their families, plus inadequate utilization of 
pharmacological and psychosocial interventions, and proper patient monitoring. There is still low 
implementation of deinstitutionalization across many, especially Central and Eastern European 
countries [[81]]. Taking patients out of the hospitals, back to their own environments, has been 
demonstrated to be beneficial to the patients while not leading to severe adverse consequences 
[[82],[83],[84]]. By deinstitutionalization, we mean a careful and responsible shift in the locus of care 
from psychiatric hospitals to communities, i.e. strongly supporting community care and families 
while making a transition and reducing the number of beds in long-term psychiatric wards.  
The reviewed data suggested a significant overlap between patient/family and professional 
perspectives - trust amongst them being the foundation for successful management throughout the 
illness course [85]. Opportunities for further improvement can be seen in various areas, as 
summarized in the Box 1. 
---Box 1 about here---  
 
 
The results of our analysis have also significant policy implications. Based on the available 
evidence and users’ needs, further supported by the economic data, we can sum up general policy 
recommendations (Box 2).  
---Box 2 about here--- 
6. Conclusions 
Most people with schizophrenia need a lifelong treatment; however, they can live their own 
life if they receive timely and proper treatment. In general, we found that the provision of early 
detection and early intervention programs is of great importance for an effective management of the 
illness. Optimal management requires a paradigm shift in the focus of schizophrenia treatment, from 
mere symptom control, achieving and maintaining remission, to the emphasis on recovery. Economic 
arguments supporting this call are provided in the accompanying report [[17]].  Changing the 
paradigm demands challenging adaptations of health and social care, moving away from 
fragmentation to a seamless care model. For this purpose, effective mental health policies are 
needed.  
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Tables and figures 
Figure 1 Intervention strategies in the early course of schizophrenia (modified from [[18]])  
(the editable PowePoint file is available – “Mohr_Figure 1_editable”) 
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Table 1: Patient and family member viewpoints  
Phase of illness/ 
intervention 
Needs and perspectives  
Premorbid phase / 
preventive measures 
• Increase awareness, knowledge and understanding of mental health problems.  
• Promote healthy lifestyle at schools (social interaction, physical activity, etc.). 
• Make psychological services at schools and universities readily accessible. 
• Manage misuse of illicit substances. 
• Reduce stigma, prejudice, and ignorance in relation to mental health problems 
and fight discrimination.  
• Encourage individuals to seek a GP/psychiatrist/psychologist/counsellor when 
experiencing mental health problems; lowering the threshold to attend primary 
care is crucial in the patient journey.  
• Prevention should start before birth; education on risk factors prior to 
conception, during pregnancy and after childbirth is important.    
Prodromal phase/  
early detection, 
early intervention 
• Raise the awareness of prodromal symptoms among health professionals, 
teachers and other educators, trainers, police, etc.  
• Psychological services at schools are crucial. 
• Educate at-risk individuals and their caregivers; address their denial; inform 
them on the access to quality services.  
• Support family organizations; establish a collaboration with mental health 
professionals. 
• All professionals involved (health, educational, social, authorities) should 
communicate with each other, as well as with families.  
• Develop apps monitoring subthreshold psychotic experiences and mood swings. 
• Develop procedures for early diagnosis.  
• Introduce clinically/biomedically based diagnosis. 
• Implement early intervention: the earlier, the better [[19]].  
• Non-pharmacological (psychosocial) interventions can be effective for 
prodromal symptoms. 
 
Acute episode / 
treatment initiation 
• Initial contact should be with medical services rather than law authorities.  
• Discuss the possible interventions covering relevant types of pharmacological 
and psychosocial treatments: objective information tailored to the patient’s 
needs is crucial (pros & cons of interventions). 
• Treatment should be personalized: the optimal mode for a specific patient 
should be selected. 
• Open communication between mental health professionals and families is 
essential. 
• Complex treatment requires therapeutic team that includes a psychiatrist, 
psychologist, social worker, case manager, family member.  
• Home visits, mobile outreach services and crisis teams can step in during crisis, 
intervene timely and effectively, prevent hospitalization. 
 
Long-term phase / 
relapse prevention 
• Patients want autonomy and participate in treatment decisions, including 
shared decision making on antipsychotic treatment. People should have quality 
options to choose from, according to their needs.  
• Patients do not want to be labeled as schizophrenic patients; they want to be 
treated as equal, with respect, to participate actively in society, to study, have a 
family, keep a job, etc. 
• Full/partial non-adherence poses a critical pitfall in the long-term management 
of schizophrenia [[20]].  
• Continuous pharmacological treatment controlling the symptoms significantly 
reduces the chance to relapse [[21]]. 
• Managing suicidal risk can reduce mortality of schizophrenia patients [[22]]. 
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• Patients generally favor psychological treatments: psychotherapy, cognitive 
remediation, can target specific symptoms and needs. 
• Patient and caregiver support groups, patients and family organizations, and 
peer programs can enhance autonomy and self-management of illness. 
• Customized psychosocial interventions, including social services, supported 
vocational services, supported housing, etc., play an important role in the long-
term management. 
• Deinstitutionalization, community settings, case management are essential.   
• Using electronic/telemetric warning signs monitoring systems may significantly 
reduce the risk of relapse [[23]]. 
Recovery • The control of symptoms is just a start, it is regarded as an important goal to 
reactivate the patient and restart his/her social activities. 
• The role of therapeutic teams addressing all aspects of recovery is essential; 
there is a need for horizontal communication. Family members should be 
integrated into care teams.   
• Psychosocial interventions + involvement of caregivers in the treatment 
pathway are crucial steps for an independent, clinically stable patient who is 
able to function. 
• Emphasis should be put on physical health, which is integral part of well-being.  
• Media campaigns may have just a short-term impact, the change of attitudes 
and style of reporting on mental health problems is crucial. 
• Prohibit explicitly discrimination on mental illness and provide support to 
patients that face discrimination.  
• Create supportive, patient friendly workplaces without discrimination, with 
appropriate processes (return to work, case review) and a proper management 
culture with occupational health and work safety strategies to support patients 
with mental illness. 
• Respond to the changing needs along the process of ageing.  
• Provide access to free legal aid.  
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Table 2: Factors affecting patients' journey 
Positive effects Negative effects 
A stable patient is able to function well in the society 
within a supportive environment, with a various 
degree of independence 
Untreated psychosis is associated with refusal of 
antipsychotic treatment and delayed help, ultimately 
leads to functional decline and poor prognosis 
Full/partial insight into the illness helps patient to 
accept and adhere to antipsychotic treatment  
Non-adherence to treatment results in repeated 
relapses with numerous negative consequences 
(neurobiological changes of the brain, unfavorable 
course and outcome of illness, poor future 
treatment response, negative socioeconomic impact 
on individuals and society, including high direct and 
indirect health costs) 
Strong therapeutic alliance (with mental health 
professionals, caregivers) yields better treatment 
outcome. 
Psychotic episode might pose a risk to the patient 
itself and for the society (suicidal ideation; 
aggressiveness, violence, victimization) 
Active patient’s participation in treatment decisions 
strengthens adherence to treatment 
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Box 1:  Opportunities for improvement in the management of schizophrenia  
• Fight stigma, raise awareness, target public opinion, policy makers, other medical professionals 
(including GP’s), media. 
• Be inspired and learn from available experiences and existing preventive programs. 
• Promote psychoeducation. 
• Develop network of outpatient and community services; improve access to social services.  
• Provide individual case management to address specific patient’s needs. 
• Make non-pharmacological therapeutic options available (CBT, cognitive remediation…). 
• Utilize new drug formulations (e.g., long-acting injectable, LAI). 
• Employ IT technologies in monitoring early warning signs and relapse prevention. 
• Use real-life (effectiveness) outcome measures beyond symptom control: subjective well-being, 
satisfaction with medication, quality of life, functional recovery. 
• Focus on somatic health of patients, improve their physical well-being.  
• Reduce burden of comorbidities (e.g., substance abuse). 
• Engage patients in treatment decisions. 
• Support active involvement of families and families organizations 
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Box 2: Policy recommendations 
• Promote and facilitate efficient health services organization: develop integrated community care and 
the cooperation of caregivers, social workers, nurses, psychologists, specialists, families, and peers. 
• Improve economic aspects (cost-effectiveness) of the systems: promote early detection programs and 
utilize most already available treatments. 
• Consider evidence-based resource allocations, support neuroscience research. 
• Governmental financial incentives are needed to create the optimal environment to succeed 
• Shift policy recommendations from reducing high costs of brain disorders to modification of health 
systems. Close the gap between public policies and practice. 
• Support volunteers: it is efficient in terms of cost and should be empowered by professionals and 
responsible authorities.   
• Raise awareness of general public and other medical professionals; fight stigma. 
• Support patients and groups of caregivers for information, expertise, sharing experiences, and 
advocacy. 
• Facilitate the establishment of active partnerships and cooperation with other stakeholders, e.g. the 
media organizations (local, regional, national, European and academic institutions), employers and 
trade unions, pharmaceutical industry, governments, regulatory bodies and insurers with a goal to 
o secure the best possible treatment for patients with a mental illness and at the earliest possible 
opportunity 
o support the development of health/mental health policies which take into account patients’ 
perspective 
 
